The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1480861
A retrospective study of neoadjuvant novel hormonal therapy prior to radical prostatectomy for high-risk prostate cancer
Provisionally accepted- First People's Hospital of Yibin, Sichuan, China
Purpose: This study aims to retrospectively describe the perioperative outcomes and short-term oncological outcomes of high-risk prostate cancer patients treated with neoadjuvant novel hormonal therapy (NNHT) combined with radical prostatectomy (RP) or RP alone.Materials and Methods: Fifty-five male patients underwent RP and were categorized based on whether NNHT was administered preoperatively. Clinical baseline characteristics, perioperative outcomes, and biochemical recurrence (BCR) rate were summarized using mean, standard deviation, medians, interquartile ranges, and frequencies. Group 1 (n=20) received NNHT in combination with RP, while Group 2 (n=35) received RP alone. Patients in the NNHT group received androgen deprivation therapy (ADT) combined with either abiraterone (1,000 mg/d), enzalutamide (160 mg/d), or apalutamide (240 mg/d) before RP. SPSS Statistics 27 was used for statistical analysis.Results: Among the 55 patients included in the study, the age, clinical T stage, N stage, biopsy Gleason scores, and the number of biopsy-positive needles appeared comparable across the two groups. However, patients in the NNHT+RP group had higher median preoperative serum prostate-specific antigen (PSA) levels (39.3 ng/mL, interquartile range [IQR]: 13.9-92.3) compared to the RP-only group (15.6 ng/mL, IQR: 10.7-19.8). The NNHT+RP group showed a lower proportion of positive surgical margins (PSM) (20%) compared to the RP-only group (49%). Similarly, the proportion of patients experiencing biochemical recurrence (BCR) within the follow-up period appeared lower in the NNHT+RP group (30%) compared to the RP-only group (57%). Additionally, operative time, hemoglobin decrease, transfusion rate, catheterization time, pathological T stage, and overall complication rates showed similar distributions across the two groups.Conclusion: This study suggests that NNHT+RP may be associated with lower rates of PSM and BCR compared to RP alone. However, further studies with larger cohorts and longer follow-up are needed to assess its long-term impact on survival and other outcomes.
Keywords: Neoadjuvant Therapy, Radical Prostatectomy, High-risk prostate cancer, Biochemical Recurrence, Retrospective study
Received: 14 Aug 2024; Accepted: 27 Jan 2025.
Copyright: © 2025 Shuai, Zhang, Liu, Zhang, Chang and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wei Zhang, First People's Hospital of Yibin, Sichuan, China
Jianping Liu, First People's Hospital of Yibin, Sichuan, China
Peng Zhang, First People's Hospital of Yibin, Sichuan, China
Congwang Chang, First People's Hospital of Yibin, Sichuan, China
Guanghua Fu, First People's Hospital of Yibin, Sichuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.